logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Marc Van den Eynde

UCLouvain
H指数:29
被引数:6,465

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune microenvironment and noncoding RNA shape early colorectal carcinogenesis in patients with premalignant lesions

免疫微环境和非编码RNA塑造具有癌前病变患者的早期结直肠癌发生

Science Translational Medicine
IF14.6
2026-06-100
PRE
Erwan Morgand; Marc Van den Eynde; Ha Nguyen; Anne-Françoise Batto; Bernhard Mlecnik; Pamela Baldin; Amine Majdi; Tessa Fredriksen; Lucie Lafontaine; Gabriela Bindea; Fariza Mezine; Mohammad Shararah; Angela Vasaturo; Assia Hijazi; Bénédicte Buttard; Pauline Maby; Rodrigo Nalio Ramos; Paula Gragera; Amos Kirilovsky; Carine El Sissy; Florence Marliot; Franck Pagès; Fazulur Rehaman Vempalli; Wouter Hendrickx; Tariq Masoodi; Michele Ceccarelli; Davide Bedognetti; Jérôme Galon
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Zanzalintinib联合atezolizumab与regorafenib对比治疗难治性结直肠癌(STELLAR-303)：一项随机、开放标签、III期临床试验

The Lancet
IF97.3
2025-10-200
PRE
J Randolph Hecht; Young Suk Park; Josep Tabernero; Myung-Ah Lee; Soohyeon Lee; Anna C Virgili; Marc Van den Eynde; Elisa Fontana; Marwan Fakih; Gholamreza Asghari; Jane So; Alexander Stein; Olivier Dubreuil; Lubomir Bodnar; Cixin Steven He; Guan Wang; Robina Smith; Cathy Eng; Anwaar Saeed
Impact of the tumor immune contexture in microsatellite-stable metastatic colorectal cancer treated with avelumab, cetuximab, and irinotecan

微卫星稳定型转移性结直肠癌接受阿维鲁姆单抗、西妥昔单抗和伊立替康治疗后，肿瘤免疫微环境的影响

Cell Reports Medicine
IF10.6
2025-06-240
OAAI
Nicolas Huyghe; Elena Benidovskaya; Tariq Masoodi; Isabelle Sinapi; Astrid De Cuyper; Fazulur Vempalli; Simon Beyaert; Caroline Bouzin; Finoula Maestre Osorio; Luigi Ferraro; Nicolas van Baren; Raphaël Helaers; Pierre Goffette; Benoit Ghaye; Aline van Maanen; Marie-Laure Castella; Michele Ceccarelli; Davide Bedognetti; Jérôme Galon; Wouter R.L. Hendrickx; Javier Carrasco; Marc Van den Eynde
A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)

一项关于奥潘奈利（ompenaclid，RGX-202-01）与安慰剂在联合FOLFIRI方案加贝伐珠单抗（BEV）治疗既往接受过治疗的RAS突变（RASmt）晚期/转移性结直肠癌（mCRC）患者中的随机双盲II期研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Elez Fernandez, M. E.; Rosello Keranen, S.; Paez, D.; Jimenez Castro, J.; Rivera Herrero, F.; Ruiz-Casado, A.; Riesco Martinez, M. C.; Montagut Viladot, C.; Coupez, D.; Ducreux, M. P.; Loly, C.; Martin-Babau, J.; Prenen, H.; van den Eynde, M.; Borg, C.; Cuyle, P-J.; de Haar-Holleman, A.; Raimbourg, J.; Bechar, N.; Tabernero, J.
Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
ANNALS OF ONCOLOGY
IF65.4
2024-06-010
PRE
Sclafani, F.; Bregni, G.; Assaf, I.; Puleo, F.; Vergauwe, P.; Prenen, H.; Diaz, M.; Gokburun, Y.; Sanchez, A. Veron; Anthoine, G.; Moretti, L.; Galdon, M. Gomez; Liberale, G.; Martinive, P.; Geboes, K.; Carrasco, J.; van den Eynde, M.; van Laethem, J-L.; Buyse, M. E.; Hendlisz, A.
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study

替雷利珠单抗对比化疗作为欧洲和北美晚期或转移性食管鳞状细胞癌患者二线治疗：RATIONALE-302随机化Ⅲ期研究的亚组分析

ESMO OPEN
IF8.3
2024-01-012
OAAI
Ajani, J.; El Hajbi, F.; Cunningham, D.; Alsina, M.; Thuss-Patience, P.; Scagliotti, G. V.; Van den Eynde, M.; Kim, S-b.; Kato, K.; Shen, L.; Li, L.; Ding, N.; Shi, J.; Barnes, G.; Van Cutsem, E.
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial
DIGESTIVE AND LIVER DISEASE
IF3.8
2023-04-019
OAAI
Aparicio, Thomas; Bouche, Olivier; Etienne, Pierre-Luc; Barbier, Emilie; Mineur, Laurent; Desgrippes, Romain; Guerin-Meyer, Veronique; Hocine, Faycal; Martin, Jean; Le Brun-Ly, Valerie; Cretin, Jacques; Desrame, Jerome; Rinaldi, Yves; Cany, Laurent; Falandry, Claire; Lefevre, Leila Bengrine; Marous, Miguelle; Terrebonne, Eric; Mosser, Laurent; Turpin, Justine; Turpin, Anthony; Bauguion, Lucille; Reichling, Cynthia; Van den Eynde, Marc; Carola, Elisabeth; Hiret, Sandrine
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial
ANNALS OF ONCOLOGY
IF65.4
2021-09-010
OAAI
Aparicio, T.; Bouche, O.; Etienne, P. L.; Barbier, E.; Mineur, L.; Desgrippes, R.; Hocine, F.; Martin, J. J.; Lebrun-Ly, V.; Cretin, J.; Desrame, J.; Rinaldi, Y.; Cany, L.; Falandry, C.; Terrebonne, E.; Mosser, L.; Pauwels, M.; Turpin, A.; Van den Eynde, M.; Hiret, S.

研究方向

暂未获取到该数据
J
Javier Carrasco
H 指数:43论文数:187被引数:4,930
J
Jérôme Galon
H 指数:98论文数:506被引数:6.9万
B
Bernhard Mlecnik
H 指数:41论文数:180被引数:3.4万
P
Paméla Baldin
H 指数:19论文数:114被引数:1,496
A
Alain Hendlisz
H 指数:42论文数:362被引数:1.1万
G
Gabriela Bindea
H 指数:35论文数:116被引数:2.5万
A
Anne Jouret‐Mourin
H 指数:20论文数:86被引数:4,045
N
Nicolas D. Huyghe
H 指数:10论文数:45被引数:705
A
Astrid De Cuyper
H 指数:9论文数:38被引数:226
E
Eric Van Cutsem
H 指数:174论文数:1,832被引数:17.4万